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APOBEC3s (A3s) are single-stranded DNA cytosine deaminases that provide innate immune defences
against retroviruses and mobile elements. A3s are specific to eutherian mammals because no direct
homologs exist at the syntenic genomic locus in metatherian (marsupial) or prototherian (monotreme)
mammals. However, the A3s in these species have the likely evolutionary precursors, the antibody gene
deaminase AID and the RNA/DNA editing enzyme APOBEC1 (A1). Here, we used cell culture-based
assays to determine whether opossum A1 restricts the infectivity of retroviruses including human
immunodeficiency virus type 1 (HIV-1) and the mobility of LTR/non-LTR retrotransposons. Opossum
A1 partially inhibited HIV-1, as well as simian immunodeficiency virus (SIV), murine leukemia virus
(MLV), and the retrotransposon MusD. The mechanism of inhibition required catalytic activity, except
for human LINE1 (L1) restriction, which was deamination-independent. These results indicate that
opossum A1 functions as an innate barrier to infection by retroviruses such as HIV-1, and controls LTR/
non-LTR retrotransposition in marsupials.
Apolipoprotein B (apoB) mRNA editing enzyme catalytic subunit 1 (APOBEC1, A1) is a cytidine deaminase that
physiologically edits apoB mRNA, which encodes a key protein involved in lipid transport1–3. A1 is a member
of the AID/APOBEC family, which catalyses the conversion of cytosines to uracils within single-stranded DNA
and RNA polynucleotides4,5. In this family, the APOBEC3 members (A3s; mainly human A3F and A3G) are
well-characterised innate immune effector proteins that restrict the spread of retroviruses and LTR/non-LTR
retrotransposons4,6–8.
Cell culture experiments have demonstrated that A1 enzymes are capable of inhibiting the replication of
HIV-1, regardless of the presence of the HIV-1 Vif protein9–12. Analogous to A3 enzymes, A1 is encapsidated
into assembling viral particles, and deaminates cytosines to uracils in nascent single-stranded viral cDNAs during reverse transcription10,11. This activity results in hallmark genomic strand G-to-A mutations. In addition,
genomic strand C-to-T mutations are readily detectable indicating that A1 enzymes also have the capacity to edit
viral genomic RNA10–12. Further cell culture studies have shown that A1 enzymes can suppress the infectivity
of several viruses such as SIV, feline immunodeficiency virus (FIV), MLV, hepatitis B virus (HBV), and herpes
simplex virus 1 (HSV-1)11,13–16 and the mobility of autonomous retrotransposons17,18. Although the biological
functions of A1 in controlling viral infection and mobile elements in vivo remain unclear, the fact that proviral
DNAs recovered from HIV-1-infected rabbit macrophages contained hallmarks of A1-mediated deamination
suggests that A1 is a natural barrier to retroviral infection19. However, studies in A1-null mice did not support the
function of A1 in blocking Friend retroviral infection in vivo20.
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Figure 1. Mutagenic activity of opossum A1 in E. coli. (a) Dot plots reporting the mutagenic activity of the
indicated constructs (RifR colonies per 107 viable cells). Data are plotted relative to the vector control (n =  5,
median with range). (b) Immunoblot of the indicated A1s expressed in bacteria.

The grey, short-tailed opossum, Monodelphis domestica, belongs to the Metatheria, which is one of the three
major groups of modern mammals and the closest relative of the Eutheria (Fig. S1a). Although eutherians encode
at least one A3 family protein, there is no A3-like gene in the genomes of non-eutherian mammals (Fig. S1b),
which was confirmed by the opossum genomic DNA sequence21, a pan-species Z1 PCR analysis22 and a BLAST
search in this study (Fig. S1b). These observations suggest that the contribution of A1 to the innate immunity
pathways of the marsupials could be greater than their contribution in eutherian mammals.
The opossum A1 is a protein of 235 amino acids that shares ~70% amino acid identity with those encoded by
eutherian mammals (Fig. S2). Although the ability of this protein to edit apoB mRNA has previously been characterised23, whether it inhibits retroviruses including HIV-1 and LTR/non-LTR mobile elements remains to be
determined. We addressed these questions using cell culture-based assays and found that opossum A1 from the
small intestine is capable of restricting the infectivity of several retroviruses and the mobility of LTR/non-LTR
retrotransposons. Taken together, our data indicate that the ability of A1 enzymes to protect the host genome
from the invasion of foreign nucleic acids is conserved in marsupial and eutherian mammals.

Results

Opossum A1 is mutagenic in Escherichia coli.

Although the A1 protein encoded in marsupials can edit
a synthetic apoB mRNA substrate23, its DNA-editing activity has not been determined. The bacterial mutator
assay is widely used to evaluate the mutagenic activity of the AID/APOBEC family proteins17,18,24–26. In this assay,
the expression of these proteins enhances the mutation of the bacterial RNA polymerase beta (rpoB) gene, which
is reported as the frequency of rifampicin resistant (RifR) colonies. Therefore, we used this system to measure the
mutagenic activity of opossum A1 by counting the RifR mutant colonies that emerged during growth of multiple
independent cultures (Fig. 1a). A1 cDNA was isolated from opossum small intestine and cloned into an expression vector. Consistent with previous observations12,18, rabbit A1 increased the number of RifR colonies (24.1-fold
relative to the vector control), whereas human A1 had only a slight effect (2.1-fold). Interestingly, the expression
of wild-type (WT) opossum A1 in bacteria markedly enhanced the frequency of rpoB mutations (390-fold).
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Opossum A1

Figure 2. HIV-1 restriction by opossum A1. (a) Representative single-cycle assays with WT opossum A1
or deaminase-defective mutants (E62A or E62Q). Viral infectivity is plotted relative to vector control and is
proportional to luciferase activity (n =  3, average +/−  SD). P values are derived by comparisons with vector
control data. (b) Representative single-cycle assays with varying concentrations of WT opossum A1 (10, 50 and
250 ng). Data represent the luciferase activity relative to vector control data (n =  3, average +/−  SD; P-values as
above). (c) Immunoblots of A1 in viral particles and cell lysates. A1 and HIV-1 Gag were detected using anti-HA
anti-p24 antibodies, respectively. β-actin expression was used a loading control. (d) A histogram showing the
relative packaging efficiency of each A1 construct. Band intensity of each HA-tagged A1 was normalised to the
corresponding p24 level. Packaging efficiency is shown graphically relative to the packaging of rabbit A1 (n =  3,
average +/−  SD). P values represent comparisons with rabbit A1 data.

However, this mutator phenotype was completely abrogated in catalytic mutant derivatives of opossum A1, E62A
and E62Q (0.7-fold), even though they were expressed at levels similar to those of WT opossum A1 (Fig. 1b).
These results demonstrate that opossum A1 has greater mutagenic activity than rabbit A1 in this E. coli-based
mutation assay.

Opossum A1 partially restricts HIV-1 infection.

Several cell-based studies have demonstrated that the
A1 proteins of rabbit and rodents inhibit HIV-1 replication independently of HIV-1 Vif expression9–12. To determine whether opossum A1 suppresses HIV-1 infectivity, we performed single-cycle HIV-1 infection assays in
HEK293T cells. As expected, rabbit A1 caused a ~200-fold reduction in HIV-1 infectivity, with significant levels
of A1 packaged into viral particles (Fig. 2). WT opossum A1 also inhibited HIV-1 replication compared with the
vector control (~2-fold; P < 0.01), and the antiviral activity of opossum A1 was dose-dependent (Fig. 2a,b). The
packaging level of the opossum protein was 2-fold lower than that of rabbit A1 (Fig. 2c,d). The antiviral activity
of the WT opossum protein was abolished in the catalytic mutants, E62A and E62Q, regardless of the packaging
level of the E62A mutant. These results indicate that opossum A1 partially restricts HIV-1 infectivity, and this
restriction requires a catalytically active enzyme.

Opossum A1 mainly localises to the nucleus. It has been demonstrated that the degree of A1 cytoplasmic localisation correlates with anti-HIV1 activity12. To assess this relationship here, we examined the subcellular localisation of opossum A1 in HeLa and HEK293T cells. The rabbit A1, which is the most active A1
protein against HIV-111, was mainly distributed in the cytoplasm of both HeLa and HEK293T cells, where ~70%
of the total signal was observed (Fig. 3a,b, S3). In contrast, ~80% of the total signal for WT opossum A1 was
detected in the nuclei of both HeLa and HEK293T cells. The catalytic mutant E62A displayed the same subcellular
ScIenTIfIc RepOrts | 7:46719 | DOI: 10.1038/srep46719
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Figure 3. Subcellular localisation and expression levels of opossum A1 in HeLa cells. (a) Representative
images showing HA-tagged A1s in green (FITC) and nuclei in blue (DAPI). (b) Quantification of the subcellular
distribution of the indicated A1 constructs. The percentage nuclear and cytoplasmic localisation is indicated
as the graphs (n =  20, average +/−  SD). P values represent comparisons with rabbit A1. (c) Nuclear (N)
and cytoplasmic (C) expression levels of A1s. Each cell fraction was blotted and probed with anti-HA, antiHSP90, and anti-TOPOIIa antibodies. (d) Relative abundance of each A1 in nuclear or cytoplasmic fractions
(percentage calculated based on combined intensity of C and N bands).

localisation in HeLa and HEK293T cells as the WT protein. However, the E62Q mutation impaired the distribution of the protein, and the mutant protein was detected in the cytoplasm, implying aberrant localisation. These
findings were confirmed by immunoblotting fractionated cell extracts (Fig. 3c,d). These results suggest that the
moderate antiviral activity of opossum A1 correlates, at least in part, with lower steady state cytoplasmic levels of
protein in cells.

Opossum A1 partially restricts SIVs and MLV. We have also demonstrated that the A1 proteins of rabbit

and rodents inhibit the replication of several retroviruses including SIVs from rhesus macaque and African green
monkey, and MLV11. To assess the capacity of opossum A1 to inhibit other retroviruses in addition to HIV-1, SIV
and MLV pseudotyped viruses encoding a reporter gene were produced in the presence of opossum A1, and the
effect of opossum A1 on retroviral replication was evaluated by infecting into HEK293T cells. Consistent with
previous observation11, rabbit A1 inhibited the single cycle infection of SIVs from rhesus macaque and African
green monkey (Fig. 4a to c), and MLV (Fig. 4d). A reduction in the infectivity of these viruses was also observed
in the presence of opossum A1, and the degree of inhibition was similar to that of the anti-HIV-1 activity (see
Fig. 2a,b versus Fig. 4a,c,d). The anti-retroviral activity against SIVs and MLV was similarly diminished by catalytic glutamate mutations (Fig. 4a,c,d), suggesting that catalytic activity is required for the restriction of these
retroviruses by opossum A1. Thus, taken together with the HIV-1 data discussed above, these HEK293T-based
experiments indicate that opossum A1 may have broad anti-retroviral activity.

Opossum A1 inhibits human L1 retrotransposition using a deaminase-independent mechanism. We have previously shown that the A1 homologues of eutherian mammals use a deaminase-independent
mechanism to inhibit L1 retrotransposition in human cell lines18. We tested the ability of opossum A1 to inhibit
human L1 retrotransposition using enhanced green fluorescent protein (EGFP)-based retrotransposition assays

ScIenTIfIc RepOrts | 7:46719 | DOI: 10.1038/srep46719
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Figure 4. Inhibition of SIV and MLV replication by opossum A1. (a) Representative SIVmac single-cycle
assays with varying concentrations (50 and 250 ng) of WT opossum A1 or deaminase-defective mutants (E62A
or E62Q). Data represent the luciferase activity relative to vector control data (n =  3, average +/−  SD with P
values represented by asterisks). (b) Immunoblots of A1 in viral particles and cell lysates. A1 and SIVmac Gag
were detected using anti-HA anti-p27 antibodies, respectively. β-actin was used a loading control.
(c) Representative SIVagm single-cycle assays with varying concentrations (50 and 250 ng) of WT opossum
A1 or deaminase-defective mutants. Data represent the luciferase activity relative to vector control data (n =  3,
average +/−  SD). P values represent comparisons with vector control data. (d) Representative MLV singlecycle assays with varying concentrations (60 and 300 ng) of WT opossum A1 or deaminase-defective mutants.
Data represent the percentage of GFP+ cells relative to vector control data (n =  3, average +/−  SD). P values
represent comparisons with vector control data.

in HEK293T cells18,27. Consistent with our previous observation18, rabbit A1 suppressed human L1 retrotransposition (~25-fold) (Fig. 5a,b). Similarly, human L1 retrotransposition was reduced ~7.7-fold in the presence of
WT opossum A1 (500 ng), and the level of suppression was proportional to the amount of enzyme expression.
This anti-L1 activity was not abolished by the inactivation of the deaminase activity of opossum A1 (Fig. 5a,
E62A and E62Q). The anti-L1 activity of opossum A1 was also supported by similar results with neo-marked L1
retrotransposition assays in HeLa cells (Fig. 5c,d). These data indicate that opossum A1 inhibits human L1 retrotransposition independently of its catalytic activity.

Opossum A1 suppresses MusD retrotransposition. It has been shown that eutherian mammal A1 proteins also inhibit the mobility of LTR retrotransposons18. To test whether this activity is present in the opossum
A1, we performed a neo-marked MusD retrotransposition assay in HeLa cells. As previously observed, rabbit A1
reduced MusD retrotransposition by ~4-fold (Fig. 6a). In the presence of opossum A1, a 2-fold reduction in the
MusD retrotransposition frequency was observed, and this reduction was abolished when catalytic mutants E62A

ScIenTIfIc RepOrts | 7:46719 | DOI: 10.1038/srep46719
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Figure 5. Restriction of L1-GFP retrotransposition by opossum A1. (a) Representative L1RP-GFP
retrotransposition assays with varying concentrations (20, 100, or 500 ng) of WT opossum A1, or its catalytic
mutants (E62A or E62Q). Retrotransposition frequency is presented relative to vector control data (n =  3,
average +/−  SD). P values represent comparisons with vector control data. (b) Immunoblotting of the indicated
HA-tagged A1s expressed in HEK293T cells, with β-actin as the loading control. (c) A representative L1-neo
retrotransposition assay with opossum A1 WT, or its catalytic mutants (E62A or E62Q). Retrotransposition
frequency is presented relative to vector control data (n =  3, average +/−  SD). P values represent comparisons
with vector control data. (d) Immunoblotting of the indicated HA-tagged A1s expressed in HEK293T cells, with
β-actin as the loading control.

and E62Q were tested (Fig. 6b). These findings indicate that opossum A1 inhibits MusD retrotransposition in a
deaminase-dependent manner.

Opossum A1 mRNA is widely expressed in primary tissues in vivo.

A1 mRNAs from rabbit18,
mouse18,28, and rat28,29 are broadly expressed in primary tissues such as the small intestine, spleen and gonads
including both testis and ovary. In contrast, the expression of human A1 mRNA is largely limited to gastrointestinal tissues30,31. We quantified the expression level of opossum A1 mRNA in several primary opossum tissues.
As anticipated, opossum A1 mRNA was abundantly expressed in the small intestine (280-fold compared with
the ovary), where it appears that A1 edits its apoB mRNA (Fig. 7). Interestingly, opossum A1 mRNA was widely
expressed in several tissues including the testis (22-fold) and lymphoid tissues (thymus, 4.1-fold; spleen, 3.3-fold)
(Fig. 7). This expression pattern appears to be different from that of human A1, which was not reported to be
expressed in the testis and lymphoid tissues30,31.

Discussion

A3 enzymes are specific proteins of eutherian mammals that are involved in the innate immunity pathways
directed against retroviruses and retrotransposons4–8. A3 homologs do not appear to exist in non-eutherian mammals such as the opossum21,22 (Fig. S1b). In this study, we used a series of cell culture studies to examine whether
opossum A1 has activity against retroviruses and LTR/non-LTR retrotransposons. Our results show that opossum
A1 inhibits retrovirus replication and MusD retrotransposition in a deaminase-dependent manner (Figs 2, 4 and
6). This enzyme also suppresses human L1 retrotransposition in a deaminase-independent manner (Fig. 5). These
results suggest that A1 plays role in protecting marsupial host genomes from parasitic genetic elements.
Despite potent mutagenic activity in bacteria (Fig. 1), opossum A1 showed modest HIV-1 restriction activity
in HEK293T cells (Fig. 2). This relatively weak phenotype may reflect the predominantly nuclear localisation of
opossum A1 in comparison to the more potent and predominantly cytoplasmic rabbit A1 enzyme (Figs 3 and
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(b) MusD retrotransposition data with WT opossum A1 or deaminase-defective mutants (E62A and E62Q).
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S3). These results are consistent with our prior studies reporting that the degree of nuclear localisation of A1
correlates inversely with its antiviral activity12. It is likely that the nuclear distribution of opossum A1 prevents
interaction with the Gag nucleocapsid protein, which in turn reduces encapsidation into virions. Alternatively,
the physiological localisation of opossum A1 could differ from its localisation when overexpressed experimentally
because endogenous A1 levels are below the limit of detection with currently available antibodies32. Furthermore,
the nuclear localisation of A1 enzymes from different species appears to be influenced by cell-type33, suggesting
that cellular factors regulate A1 localisation. A1s are expected to be more active against HIV-1 when they are in
the cytoplasm. It must be noted that a chimeric human A1 fused to the rabbit homologue redistributed to the
cytoplasm from the nucleus, was packaged more efficiently, and subsequently inhibited HIV-1 infectivity more
effectively than the original human A1 protein12. Further studies, including the development of more sensitive
antibodies and the identification of cellular factors that regulate the subcellular localisation of A1 will clarify the
correlation between the subcellular localisation of A1 and its anti-HIV-1 activity.
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Our cell-based assays did not use opossum cells and, to our knowledge, vectors have yet to be developed for
opossum viruses and mobile elements. Nevertheless, the results presented here suggest that A1 likely functions as
an innate barrier to infection by retroviruses and controls LTR/non-LTR retrotransposition in marsupials. First,
opossum A1 possesses restriction activity against several different retroviruses (Figs 2 and 4) and LTR/non-LTR
retroelements (Figs 5 and 6). Second, ~50% of the opossum genome is composed of repetitive elements (LINEs:
~29%, SINEs: ~10%, endogenous retroviruses: ~11% and DNA transposons: ~2%)21. Of note, the proportion of
LINEs in the opossum genome is approximately 1.5 times higher than that in human and mouse genomes (~20%
LINE). The greater anti-L1 activity of opossum A1 in comparison to anti-retroviral activity might be associated
with the relatively higher proportion of LINEs in the opossum genome. Third, A1 mRNA is expressed in many
different opossum tissues (Fig. 7), which is distinct from the gastrointestinal expression profile of A1 in human
tissues30,31. This broad expression profile suggests that opossum A1 has additional functions besides editing of
apoB mRNA. Future investigations should include the development of an infectious molecular clone using viruses
that naturally infect opossum and assay systems using opossum cells, to determine whether opossum A1 is indeed
a bona fide anti-viral restriction factor.
One of the common functions among AID/APOBEC family proteins is restriction of non-LTR retrotransposon, L1, using a mechanism that is independent of enzymatic activity17,18,34–38. However, it has been proposed that
the mechanism by which L1 retrotransposition is suppressed by A1 is different from the deamination-independent
mechanisms used by A3 enzymes17. In contrast to human A3s that are able to restrict human L1 retrotransposition even in the absence of a L1-encoded ORF1 protein39, A1s from human and lizard require the binding to L1
ORF1 protein for the inhibition of human L1 retrotransposition17. Interestingly, human and mouse ORF1 proteins form ribonucleoprotein (RNP) complexes with L1 RNA40,41, and the targeting of the L1 RNP complexes into
cytoplasmic foci like stress granules is likely to control L1 retrotransposition42,43. It is noteworthy that human L1
RNA is found in A1 RNP complexes when they are cotransfected into HEK293T cells18. These observations suggest that the formation of A1 RNP complexes could sequester L1 RNA and/or ORF1 protein from its appropriate
trafficking and translation, and ultimately could interfere with its retrotransposition into genome. This is also in
contrast to A3s that are not necessary to form intracellular RNP complexes for L1 inhibition36. It is unclear what
steps of L1 replication the A1 and A3 enzymes affect using deaminase-independent mechanisms. Elucidation of
this deamination-independent repressive activity of APOBECs on L1 retrotransposition may provide important
insights into the continuous arms race between viruses and their hosts.
It has been demonstrated that A1s from amniotes, including eutherian mammals, inhibit L1 retrotransposition in vitro17,18, and that these A1s also function as DNA mutators18,44. However, although A1 is expressed in
the lizard, no deamination at the site corresponding to mammalian apoB mRNA editing has been observed44,
suggesting that RNA editing may not be the ancestral function of A1. Because opossum A1 has RNA editing
activity against apoB mRNA23, it appears that at least the A1s of mammals acquired the ability to edit apoB mRNA
after the divergence of this group from the common ancestor they shared with other vertebrates (i.e., amphibians
and birds). Therefore, the most likely original function of A1 was probably DNA editing and protecting cells
against mobile elements, because the A1s of amniotes, including mammals, maintain anti-L1 activity in vitro17,18.
Although several studies have suggested that non-human A1s (e.g., rabbit A1) may be involved in innate immune
pathways11,13,14,16,18,19, it seems that the function of human A1 is limited to editing apoB mRNA in the small
intestine30, and that the functions of A1 in innate immunity have been taken over by the expansion of A3s in the

ScIenTIfIc RepOrts | 7:46719 | DOI: 10.1038/srep46719

8

www.nature.com/scientificreports/
primate lineages such as in humans. Further studies are needed to shed light on the evolutionary history of RNA
editing by the A1 deaminases and on their ancestral and physiological functions other than apoB mRNA editing.

Methods

Cells and antibodies. HEK293T, and HeLa cells were maintained in Dulbecco’s modified Eagle’s medium
supplemented with 10% bovine fetal serum (Gibco, Life Technologies). The anti-p24 capsid (CA) antibody used
has been described previously45. The anti-SIVmac p27 antibody (55-2F12, #1610)46 was obtained from the NIH
AIDS Reagent program. Antibodies against hemagglutinin (HA; C29F4, Cell Signaling Technologies, and HA.11,
Covance), HSP90 (AC88, Stressgen), TOPOIIa (#4733, Cell Signaling Technologies), and β-actin (AC-74, Sigma)
were commercially available.
DNA constructs. Vectors expressing Vif-proficient HIV-1, SIVmac and SIVagm proviral DNAs (pNL4-3
Luc E−R−, SIVmac Luc E−R− and SIVagm Luc E−R−, kindly provided by N.R. Landau, New York University)47,
EGFP-based human L1 (pL1RP-EGFP, kindly provided by E.T. Luning Prak, University of Pennsylvania) 27,
neoR-gene-marked human L1 (pCEP4/L1mneoI/ColE1, kindly provided by N. Gilbert, Institut de Génétique
Humaine, CNRS)48, and neoR-gene-marked murine MusD (pCMV L1Mus-6DneoTNF, kindly provided by T.
Heidmann, Institut de Cancérologie Gustave Roussy)49 have been described elsewhere. The generation of a
C-terminal HA-tagged rabbit A1 expression plasmid and bacterial expression plasmids encoding HA-tagged
human and rabbit A1s has been described previously18.
Cloning of opossum A1 cDNA. Production, maintenance and experimental manipulations of the animals
were approved by the Institutional Animal Care and Use Committee of the Texas Biomedical Research Institute
(John L. VandeBerg; previous affiliation). All procedures were carried out in accordance with the approved guidelines. Small intestine has been removed aseptically from euthanized Monodelphis Domestica (opossum). Total
RNA was isolated using TRIzol reagent (Invitrogen), and then treated with DNase I (Takara). cDNA encoding the opossum A1 gene was synthesised using the High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems) with a primer set designed so that a single HA epitope tag was attached to the C-terminus of the
protein as previously described23. (5′-NNNNNGATATCGAAGCCATGAATTCTAAGACAGGTCCA-3′ and
5′-NGCGGCCGCTCAAGCGTAATCTGGAACATCGTATGGGTATCTCCAGGTCACAAATGGCTGG-3′,
Restriction enzyme sites are underlined). The amplified fragment was cloned into the pCR-Blunt vector
(Invitrogen) and sequenced. The amplified product was then inserted into the EcoRV and NotI sites of the
pCAGGS expression vector and sequenced. The nucleotide sequence of an open reading frame encoding opossum A1 was identical to that enrolled in GenBank (NM001032982). The catalytic mutants of the opossum A1
were constructed using the oligonucleotide primers. E62A: 5′-TCTCAACATGCTGCAATCAACTTCATG-3′
and 5′-CATGAAGTTGATTGCAGCATGTTGAGA-3′. E62Q: 5′-TCTCAACATGCTCAAATCAACTTCATGG
-3′ and 5′-CCATGAAGTTGATTTGAGCATGTTGAGA-3′. The amplified products were inserted into
the pCAGGS vector at the EcoRV and NotI sites and sequenced. Bacterial expression plasmids encoding
C-terminal HA-tagged opossum A1 and its catalytic mutants (E62A and E62Q) were created with the following primer set: 5′  - NNNNCTCGAGATGAATTCTAAGACAGGTCCATCAGTAGGAGA-3′ and 5′
-NNNATGCATTCAAGCGTAATCTGGAACATCGTATGGGTA-3′. The amplified products were then cloned
into the pTrcHis A vector (Invitrogen) with restriction enzymes XhoI and NsiI and sequenced.
Sequence alignment.

The amino acid sequences of full-length mammalian A1s were aligned as previously described11. The GenBank accession numbers of the A1 sequences used for this comparison are: human
(NM001644), rabbit (U10695), rat (MN012907), mouse (NM031159), and opossum (NM001032982).

Immunoblot analysis.

Cell and virion lysates were resolved with sodium dodecyl sulphate (SDS) polyacrylamide gel electrophoresis (PAGE), transferred to a polyvinylidene difluoride membrane (Millipore), and
blocked with 4% milk in phosphate-buffered saline (PBS) containing 0.1% Tween 20. The membranes were
then incubated with a primary antibody, a biotin-conjugated secondary anti-mouse or anti-rabbit IgG antibody (Sigma) and streptavidin-conjugated horseradish peroxidase (Sigma). The signals were visualised with
Chemi-Lumi One (Nacalai Tesque) and a VersaDoc 5000 Imager (Bio-Rad).

Subcellular localisation.

An immunofluorescence analysis was performed as previously reported12,18.
Briefly, 2 ×  104 HEK293T or HeLa cells were plated in each well of an eight-well Lab-Tek Chamber Slide (Nalge
Nunc International). The cells were transfected with the pCAGGS expression vector (500 ng) encoding either
HA-tagged rabbit A1, opossum A1, or its catalytic mutants (E62A or E62Q), using FuGENE HD (Roche). After
24 h, the transfected cells were fixed with 4% formaldehyde in PBS for 30 min, and permeabilised with 0.1%
Triton X-100 in PBS. The cells were then treated with 0.1 M glycine/PBS to quench the reaction and blocked with
0.3% bovine serum albumin (BSA)/PBS. To stain A1, the cells on coverslips were incubated with an anti-HA
antibody (HA.11; 1:1000 dilution) in 0.3% BSA/PBS in a humid chamber at 37 °C for 1 h, and then with fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse IgG antibody (Sigma; 1:300)/0.3% BSA/PBS for 1 h. The
cells were then treated with 1 μg/mL 4,6-diamidino-2-phenylindole staining (DAPI; Invitrogen) for 5 min. The
coverslips were mounted with Fluorescent Mounting Medium (Dako). Fluorescence was visualised with a Zeiss
LSM 700 laser-scanning confocal microscope. The images were captured with IPLab and processed with the
Adobe PhotoShop 4.0 software. The fluorescence intensity of A1 in the cytoplasm was calculated as previously
described12. Briefly, the total FITC signal intensity of 20 cells for each A1 was measured using Image J software.
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The intensity of FITC signal overlapped with the portion of DAPI staining was measured to calculate the proportion of nuclear distribution of A1. Then, the proportion of cytoplasmic distribution of each A1 was calculated by
subtracting the nuclear FITC signal from the total FITC signal. The densitometric analysis of the blotting bands
was quantified using an image analysis system.

Preparation of nuclear and cytoplasmic extracts. The nuclear and cytoplasmic extracts from
HEK293T were prepared with the Subcellular Protein Fractionation Kit for Cultured Cells (Thermo Fisher
Scientific), according to the manufacturer’s protocol.
Bacterial mutator assay. The generation of bacterial expression plasmids encoding cDNAs encoding
HA-epitope-tagged opossum A1 and its derivatives is described above. The Escherichia coli–based DNA mutation assay was performed as described previously12,18. The uracil DNA glycosylase (ung)-deficient E. coli strain
BW310 was transformed with the parental pTrcHisA plasmid or vectors encoding the various A1 cDNAs. Twenty
colonies of the transformed bacteria, selected on plates containing ampicillin, were cultured overnight at 37 °C
in 2 mL of LB medium containing ampicillin and 1 mM IPTG. The saturated cultures (100 μL) were then plated
on LB agar containing 100 μg/mL rifampicin. The total number of RifR colonies per plate was counted after 24 h.
The appropriate dilution of viable cells was plated onto an LB plate containing ampicillin and the mutation frequencies were calculated as RifR colonies per viable cell. To verify protein expression, 100 μL of each saturated
IPTG-induced culture was lysed and subjected to immunoblotting, as described above.
Single-cycle infection assays. HEK293T cells (2.5 ×  105) were cotransfected with 0.75 μg of Vif-proficient

NL4-3 Luc E−R− proviral DNA construct, together with 0.5 μg of pVSV-G vector and 0.25 μg of the control vector
or one of several expression vectors encoding C-terminal HA-epitope-tagged A1 protein supplemented with the
appropriate concentration of the control vector, using Effectene (Qiagen). For SIVs, 0.75 μg of Vif-proficient
SIVmac or SIVagm Luc E−R− proviral DNA construct was cotransfected into HEK293T cells, with 0.5 μg of
pVSV-G vector and 0.25 μg of the control vector or HA-tagged A1 expression vector. MLV-GFP virus stock was
produced as previously described50,51. HEK293T cells were cotransfected with 0.3 μg of MLV genome expressing
a GFP reporter M3P-GFP, together with 0.3 μg of MLV packaging construct pMD-MLV-OGP, 0.1 μg of pVSV-G
and 0.3 μg of the control vector or HA-tagged A1 expression vector. After 48 h, the virus-containing supernatants
were filtered with 0.45 μm filters and frozen as aliquots. The p24 or p27 content of the viruses was determined
with a HIV-1 p24 or SIV p27 antigen ELISA kit (ZeptoMetrix). Fresh target HEK293T cells were infected with
the equivalent amounts of the luciferase reporter viruses and after 48 h, the intracellular luciferase activity of
the infected cells was measured, as previously described11,12. Infectivity of MLV-GFP virus was analysed by flow
cytometery. To assess the packaging of the A1 proteins into viral particles, the virus-containing supernatants were
spun through a 20% sucrose cushion and the viral pellets were solubilised in 2× SDS sample buffer. Equivalent
amounts of p24 or p27 antigen from each solubilised sample were analysed with immunoblotting, as described
above. Band intensities were analysed with the ImageJ software.

®

L1 retrotransposition assays. The EGFP-based human L1 retrotransposition assay was performed as
previously described18. Briefly, 3 ×  105 HEK293T cells were cotransfected with 1.5 μg of pL1RP-EGFP or the
pIRESpuro vector (Clontech) and 0.5 μg of the control vector or the respective A1 expression vector with the
appropriate concentration of a control vector with Effectene. At 24 h posttransfection, the cells were selected
with 1.0 μg/mL puromycin and 7-9 days after selection, the EGFP expression resulting from retrotransposition
was measured with flow cytometry. The neoR-gene-marked human L1 retrotransposition assay was performed
by cotransfecting HeLa cells (5 ×  105 cells) with 0.4 μg of the respective A1 expression plasmid and 1.2 μg of the
human L1-neo reporter vector together with 0.4 μg of pIRES-EGFP (Clontech) as the transfection control, using
FuGENE, as previously described18. After 72 h, 5 ×  105 cells were plated onto 100 mm dishes and selected with
0.75 mg/mL G418. At 12–14 days after selection, the resultant G418R colonies were stained with crystal violet
(Sigma) and counted. The retrotransposition frequency was calculated as the number of G418R colonies/transfection efficiency (percentage of GFP+ cells).
MusD retrotransposition assay.

The murine MusD retrotransposition assay was performed as previously
described18. Briefly, 5 ×  105 HeLa cells were cotransfected with 0.2 μg of the control vector or the respective A1
expression plasmid supplemented with the appropriate concentration of the control vector, together with 0.6 μg
of the neor-based murine MusD reporter vector together with 0.4 μg of pIRES-EGFP, using FuGENE. After 72 h,
5 ×  105 cells were reseeded onto 100 mm dishes for G418 (1.0 mg/mL) selection, and the resultant G418R colonies
were counted. The retrotransposition frequency was calculated as described above.

Quantitation of opossum A1 transcripts in vivo. cDNAs from opossum primary tissues were synthesized using the High Capacity cDNA Reverse Transcription Kit. Amplification was performed using
the following primers: A1, 5′-CGCGTCCACCTGATTC-3′ and 5′-CGCGTCCACCTGATTC-3′. gapdh, 5′
-CGCGTCCACCTGATTC-3′and 5′-CGCGTCCACCTGATTC-3′. PCR amplification conditions were 95 °C for
10 min, followed by 50 cycles of 95 °C for 30 s, 53 °C for 20 s, and 68 °C for 30 s. Quantitation was performed with
SYBR Green PCR master mix (Applied Biosystems) using a Realplex2 Mastercycler EPgradient S (Eppendorf).
Expression levels of target cDNA were normalized to the amount of endogenous mRNA of gapdh.
Statistical analysis. The statistical analysis was performed with Student’s t test. All data are the means and
standard deviations (SDs) of three experiments, unless otherwise stated. *P <  0.05, **P <  0.01, ***P <  0.001.
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